FASLG and neoplasm: IL-18, which is an interferon-γ-inducing factor [113], affects an antitumor effect via the activation of natural killer (NK) cells or cytotoxic T cells [113, 114], inhibition of angiogenesis [115] and induction of FasL on Fas-positive tumor cells [116].